Table 3 Univariate analysis of factors associated with 28-day mortality
Variable | Number (%) of patients | Univariate analysis | ||
|---|---|---|---|---|
Alive (n = 84) | Deceased (n = 60) | p value | OR (95% CI) | |
Demographics and comorbidities | ||||
Age (years) | 57.7 ± 15 | 61.7 ± 10 | 0.08 | 1.02 (0.99–1.05) |
Males | 58 (69.1) | 35 (58.3) | 0.19 | 0.63 (0.31–1.25) |
CHF | 24 (28.6) | 21 (35) | 0.41 | 1.34 (0.66–2.74) |
COPD | 14 (16.7) | 9 (15) | 0.79 | 0.88 (0.35–2.2) |
CRF | 8 (9.5) | 7 (11.7) | 0.68 | 1.25 (0.43–3.67) |
Diabetes | 25 (29.8) | 23 (38.3) | 0.28 | 1.47 (0.73–2.95) |
CLD | 8 (9.5) | 10 (16.7) | 0.21 | 1.9 (0.7–5.14) |
Neoplasm | 7 (8.3) | 7 (11.7) | 0.51 | 1.48 (0.48–4.38) |
Immunosuppressive status | 27 (32.1) | 18 (30) | 0.78 | 0.9 (0.44–1.85) |
ICU stay before infection (days), median (IQR) | 8.5 (1–21) | 8 (1–23) | 0.69 | 1 (0.98–1.01) |
Duration of MV before infection (days), median (IQR) | 6 (1–13.5) | 5.5 (0.5–15) | 0.79 | 1.01 (0.98–1.03) |
Duration of vasopressors before infection (days), median (IQR) | 2 (0–7.5) | 2 (0–7) | 0.68 | 0.99 (0.97–1.02) |
Presenting features, type of infection, and therapy | ||||
Medical admission | 45 (53.6) | 39 (65) | 0.17 | 1.61 (0.81–3.18) |
Surgical admission | 29 (34.5) | 15 (25) | 0.22 | 0.63 (0.3–1.32) |
Trauma admission | 10 (11.9) | 6 (10) | 0.72 | 0.82 (0.28–2.4) |
SAPS II score, median (IQR) | 39 (34–50) | 55 (45.5–63) | <0.01 | 1.07 (1.04–1.08) |
SOFA score on occurrence of infection, median (IQR) | 8 (5–9) | 9 (8–11) | <0.01 | 1.36 (1.17–1.57) |
SS on occurrence of infection | 42 (50) | 37 (61.7) | 0.17 | 1.6 (0.82–3.16) |
ARDS on occurrence of infection | 21 (25) | 20 (33.3) | 0.28 | 1.5 (0.72–3.11) |
CRRT on occurrence of infection | 22 (26.2) | 24 (40) | 0.08 | 1.88 (0.92–3.82) |
PCT on occurrence of infection (ng/ml), median (interval) | 3.4 (0.71–7.5) | 4.3 (2.3–8.6) | 0.43 | 1 (0.99–1.01) |
Type of infection and therapy | ||||
Pneumonia | 41 (48.8) | 33 (55) | 0.46 | 1.28 (0.66–2.49) |
IAI | 14 (16.7) | 5 (8.3) | 0.15 | 0.45 (0.15–1.34) |
SSTI | 8 (9.5) | 4 (6.7) | 0.55 | 0.67 (0.19–2.37) |
UTI | 6 (7.1) | 6 (10) | 0.54 | 1.44 (0.44–4.72) |
CVC BSI | 11 (13.1) | 7 (11.7) | 0.8 | 0.88 (0.32–2.41) |
Primary BSI | 9 (10.7) | 7 (11.7) | 0.86 | 1.1 (0.39–3.14) |
Secondary BSI | 30 (35.7) | 19 (31.7) | 0.61 | 0.83 (0.41–1.69) |
Polymicrobial infection | 8 (9.5) | 15 (25) | 0.01 | 3.17 (1.25–8.06) |
Double carbapenem therapy | 34 (40.5) | 14 (23.3) | 0.03 | 0.45 (0.21–0.94) |
IIAT | 26 (30.9) | 27 (45) | 0.08 | 1.82 (0.92–3.63) |
Combination targeted therapy | 48 (57.1) | 39 (65) | 0.34 | 1.39 (0.7–2.76) |
Duration of active treatment (days), median (IQR) | 14 (8–18.5) | 10 (8–14.5 | 0.13 | 0.96 (0.93–1.01) |